pretickt

CRISPR Therapeutics CRSP stock

CRISPR Therapeutics AG · Healthcare · end-of-day data as of Nov 13, 2026

CRISPR Therapeutics
CRSP · $4.1B
$42.24-0.9%
Nov 13, 2026 · close
$45$50$55$60SepOctNov9:3016:003 months -20.3%Nov 13close
▲ Bullish readings 4
  • Price target at$72.45 +71.5%
  • ConsensusBuy · 23
  • Bollingerbelow lower
  • Sector▲ +15.9%
Neutral
  • Earnings in90d
  • RSI32
  • Support-7.6%
  • Resistance+0.3%
  • Off 52w high-33.4%
  • Volume1.2x
  • News0.00
  • Trendsideways
  • 52w range$42–$63
  • ATR+6.3%
  • Off ATH-80.8%
▼ Bearish readings 4
  • FCF yield-9.3%
  • Insiders-$4.88M
  • MAs0 of 4
  • MACD-0.81

Updates with the 15-min delayed price; analysts, insiders and news are from the last close. Not a forecast or investment advice.

The average 12-month analyst price target for CRISPR Therapeutics CRSP is $72.45, 71.5% above the last close of $42.24 on Nov 13, 2026; targets range from $52.00 to $110.00. Rating consensus: Buy.

What changed

CRISPR Therapeutics CRSP · Latest: Nov 12, 2026

CRISPR Therapeutics closed at a 52-week low of $42.62 on Nov 12

The stock fell 6.8% that day, 5.7% of it on its own, and its 50-day average crossed below its 200-day average. Over the 5 sessions to Nov 12 it fell 12.2%.

  • CRISPR Therapeutics closed at a 52-week low of $42.62 on Nov 12, 2026; that was the last session.
  • Last close (Nov 12): CRSP -6.8% = market (SPY) -0.4% + Healthcare sector -0.8% + CRSP on its own -5.7%.
  • CRISPR Therapeutics' 50-day average crossed below its 200-day average on Nov 12, 2026; that was the last session.
  • Last 5 sessions to Nov 12: CRSP -12.2% = market (SPY) +3.3% + Healthcare sector -2.6% + CRSP on its own -12.9%.

Wording by an AI model from pretickt's data; the dated facts under it are the platform's own. Not investment advice.

Analyst price targets and predictions

11 firms with a target in the last 12 months · last close $42.24 · as of Nov 13, 2026

— actual price● bullish target● bearish target┄ last close, high, average and low targethover a dot to see the analysts behind it ·wheel or drag to move through time · drag the price axis on the right to stretch it · double-click resets
⇔⇕$110HIGH$72.45AVERAGE$52.00LOW$42.24TODAYNov 25Apr 26Sep 26Feb 27Jul 27Dec 27+75%+83%-22%+80%+37%+89%+30%+23%+78%+160%
31

Strong buy 4Buy 9Hold 10Sell 0Strong sell 0

23 analysts in November 2026: 13 rate it a buy or strong buy (57%) and 10 a hold. A year earlier, 62% rated it a buy or strong buy.

Is CRISPR Therapeutics a good stock to buy?

CRISPR Therapeutics is strong on 1 of the 5 questions about the business; weak on advantage, economics, execution and fragility. With a loss over the last 12 months, CRISPR Therapeutics has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage easy to copy
  3. Economics losing money
  4. Execution misses
  5. Fragility fragile
  6. Price below its peers
CRSP: the 6 questions, card by card

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.

Snapshot

  • P/E—
  • P/E vs sector—
  • P/E vs own—
  • Price target at+71.5%
  • ConsensusBuy
  • Market cap$4.1B
  • FCF yield-9.3%
  • Insiders-$4.88M
  • Earnings in90d
  • News0.00

Why it moved

CRISPR Therapeutics CRSP fell 0.9% on Nov 13, 2026.

The market (SPY) fell 0.4%; Healthcare stocks rose 0.3%. Most of the move is specific to CRISPR Therapeutics CRSP.

Market (SPY)-0.4%
Healthcare sector+0.7%
CRSP specific-1.2%

0 stories on the day (30-day average 0.8).

Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.

Price and events

⇔⇕$43.52$49.22$54.91$60.61Nov 25Feb 26May 26Aug 26Nov 26Feb 27EEEEE

Last close $42.24 · -17.4% over 1y · E earnings · D dividend · S split · A analyst rating change

Technicals

CRISPR Therapeutics CRSP closed at $42.24 on Nov 13, 2026, 19.6% below its 200-day moving average of $52.53 and 18.9% below its 50-day moving average of $52.09. It is 33.4% below its 52-week high of $63.45; its 52-week low is $41.75.

  • Trendsideways
  • Sector▲ +15.9%
  • MAs20▼ 50▼ 100▼ 200▼
  • Above MAs0 of 4 above
  • MA20×50—
  • RSI32
  • Support-7.6%
  • Resistance+0.3%
  • Off 52w high-33.4%
  • Off ATH-80.8%
  • 52w range$42.24
  • Bollingerbelow lower
  • MACD-0.81
  • ATR+6.3%
  • Volume1.2x

Revenue and free cash flow

Q3 FY2026: Revenue +1,325.1% year over year, free cash flow -711.2% of revenue, operating margin -1,026.5%.

RevenueFree cash flow
Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Q3 FY2026Sep 30, 2026$12.67M-1.15-$90.1M-225.9%-1,026.5%-879.6%
Q2 FY2026Jun 30, 2026$10.18M-0.94-$86.62M-337.8%-1,127.6%-895.3%
Q1 FY2026Mar 31, 2026$1.46M-1.28-$109M-3,346.4%-8,933.3%-8,431.5%
Q4 FY2025Dec 31, 2025$864K-1.37-$93.07M-6,770.8%-17,912.5%-15,117.2%
Q3 FY2025Sep 30, 2025$889K-1.17-$84.71M-7,177.1%-14,854.8%-11,973.1%
Q2 FY2025Jun 30, 2025$892K-2.40-$114M-5,477.7%-14,918.3%-23,379.9%
Q1 FY2025Mar 31, 2025$865K-1.58-$54.15M-6,548.4%-17,158.8%-15,722.1%
Q4 FY2024Dec 31, 2024$35M-0.44-$50.28M100.0%-184.5%-106.6%

Peers

20D
1VRTXVertex$538.60-0.7%-5.3%+6.6%34.7$137B
2REGNRegeneron$955.47+0.4%-3.7%-6.4%21.1$98.82B
3MRNAModerna$223.37-3.4%-20.5%-45.2%—$90.38B
4INCYIncyte$120.97-0.6%-8.8%+9.8%64.3$24.66B
5ALNYAlnylam$165.04+5.4%-65.6%+113.7%8.3$22.11B
6TECHBio-Techne$72.80+0.1%-0.1%-7.7%66.2$11.44B
7TWSTTwist Bioscience$111.60-2.3%-49.2%+30.6%—$7.35B
8CRSPCRISPR Therapeutics$42.24-0.9%-33.4%+71.5%—$4.1B

Data as of Nov 13, 2026 close.

Latest news

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.